Organization
Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance
11 abstracts
Abstract
Knowledge, attitudes, and practices of university students towards risk factors, screening, and perceived barriers of screening regarding colorectal cancer: A multi-country study from the eastern Mediterranean region.Org: University of Limoges, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance, Limoges University Hospital, Inserm U1094- IRD UMR270- University of Limoges- University Hospital center of Limoges- EpiMaCT - Epidemiology of chronic diseases in tropical zone - Omega Health,
Abstract
An evaluation of cell-free tumor DNA from 20 mL of peritoneal fluid for homologous recombination deficiency (HRD) testing in newly diagnosed ovarian cancer (OC).Org: Gustave Roussy Institute, Villejuif, France, France, Institut Gustave Roussy, Gustave Roussy Cancer Center,
Abstract
Impact of first-line immunotherapy on survival and intracranial outcomes from a real-world cohort of non-small cell lung cancer patients with brain metastases at diagnosis.Org: Nantes University Hospital, Institut de Cancérologie de l'Ouest, Angers, France, Nantes Université, CHU Nantes-Department of Hepato-Gastroenterology, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance,
Abstract
Development and evaluation of 5FUCore, OxaliCore, and IrinoCore transcriptomic signatures for predicting response to individual drugs in the FOLFIRINOX regimen: Towards toxicity reduction and personalized chemotherapy in PDAC.Org: Cancer Research Center of Marseille (CRCM), Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance, CNRS UMR 5309-INSERM U1209, Institut Paoli-Calmettes, Marseille, France, Aix-Marseille University CHU Timone,
Abstract
First-in-human trial of tocilizumab in combination with a standard induction chemotherapy in newly diagnosed acute myeloid leukemia patients: The phase 1 TOCILAM study.Org: CHU de Nantes, Hôpital Hôtel-Dieu, Nantes, France, Service d'Hématologie Clinique - CHU Pontchaillou, Hotel Dieu - HME, Clinical Research Centre, Departmental Hospital Centre,
Abstract
Predictive models of recurrence from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA France trials.Org: Institut du Cancer Paris CARPEM, APHP-INSERM U1149 Universite Paris Diderot, APHP.Centre - Université Paris Cité, Université Paris Cité, Hôpital Européeen G. Pompidou,
Abstract
Comparison of generic and specific anxiety in patients treated with apalutamide plus active surveillance vs active surveillance alone for low and intermediate risk prostate cancer.Org: Institut Paoli-Calmettes, Marseille, France, Aix-Marseille Universite, CRCM, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance, IRD,
Abstract
Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study.Org: Memorial Sloan-Kettering Cancer Center, Knapp Center for Biomedical Discovery, The University of Chicago Medicine Center for Advanced Care at Orland Park, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Thoraxklinik,
Abstract
BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.Org: APHP-INSERM U1149 Universite Paris Diderot, European Georges Pompidou Hospital, Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université,
Abstract
Prognostic impact of TP53 mutations in metastatic non-squamous non-small-cell lung cancer.Org: Institut de Cancérologie de l'Ouest, Angers, France, Nantes University Hospital, Nantes Université, CHU Nantes-Department of Hepato-Gastroenterology, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance,
Abstract
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.Org: Aix Marseille University - Assistance Publique Hopitaux De Marseille, APHM, Service d'Oncologie Multidisciplinaire & Innovations Thérapeutiques, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance, CNRS UMR 5309-INSERM U1209, CRCM,